This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Melodiol Global Health Beheer

Beheer criteriumcontroles 1/4

De CEO Melodiol Global Health is Will Lay, benoemd in Jan2022, heeft een ambtstermijn van 2.75 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 894.88K, bestaande uit 46% salaris en 54% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde A$ 70.81. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 2.8 jaar.

Belangrijke informatie

Will Lay

Algemeen directeur

AU$894.9k

Totale compensatie

Percentage CEO-salaris	46.0%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 01

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

Mar 02

Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

May 11

Analyse CEO-vergoeding

Hoe is Will Lay's beloning veranderd ten opzichte van Melodiol Global Health's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	AU$895k	AU$412k	-AU$36m
Jun 30 2023	n/a	n/a	-AU$54m
Mar 31 2023	n/a	n/a	-AU$43m
Dec 31 2022	AU$408k	AU$389k	-AU$22m

Compensatie versus markt: De totale vergoeding ($USD 588.46K ) Will } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 304.34K ).

Compensatie versus inkomsten: De vergoeding van Will is gestegen terwijl het bedrijf verliesgevend is.

CEO

Will Lay

2.8yrs

Tenure

AU$894,875

Compensatie

Mr. William Lay, also known as Will, B.Com (Hons.) is CEO & MD of Health House International Limited from 2024. He serves as Group Chief Executive Officer, Managing Director and Director at Melodiol Global...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Christopher Grundy	Chief Financial Officer	6.9yrs	AU$628.01k	0.00014% A$ 1.6
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Gian Trepp	Commercial & Marketing Director	5.8yrs	geen gegevens	geen gegevens
Mitchel Fleming	Managing Director of Halucenex	no data	geen gegevens	geen gegevens
Brett Ayers	Managing Director of Impactive	no data	geen gegevens	geen gegevens
Winton Willesee	Joint Company Secretary	6yrs	geen gegevens	geen gegevens
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van ME1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	geen gegevens	geen gegevens
Walter Von Wartburg	Member of Scientific Advisory Board	5.8yrs	geen gegevens	geen gegevens
Bruce Linton	Independent Non-Executive Director	2.8yrs	AU$82.72k	0.0019% A$ 22.0
Isaac Kobrin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Felix Gutzwiller	Member of Scientific Advisory Board	7.6yrs	geen gegevens	geen gegevens
Peter Hatfull	Non-Executive Director	1.9yrs	AU$83.26k	geen gegevens
Ben Quirin	Non-Executive Director	2yrs	AU$82.80k	geen gegevens

2.8yrs

Gemiddelde duur

73.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ME1 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

This company listing is no longer active

Melodiol Global Health Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

New major risk - Negative shareholders equity

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215 million.

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.231808 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 1.010906 million.

First half 2023 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in 1H 2022)

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.574725 million.

Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.

Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

First half 2021 earnings released: AU$0.018 loss per share (vs AU$0.08 loss in 1H 2020)

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.23

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd